Geron Corporation has added a new financial report to its website:

Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
Post Reply
biopearl123
Posts: 1665
Joined: Fri Jul 20, 2018 5:13 pm

Geron Corporation has added a new financial report to its website:

Post by biopearl123 » Fri May 01, 2020 4:12 am

More later.

biopearl123
Posts: 1665
Joined: Fri Jul 20, 2018 5:13 pm

Re: Geron Corporation has added a new financial report to its website:

Post by biopearl123 » Fri May 01, 2020 5:36 pm

Hat tip to hunt YMB for doing the Digging “ . If approved for marketing by regulatory authorities, we plan to commercialize imetelstat in the United States and seek potential
commercialization partners for territories outside of the United States.
We hold issued patents covering imetelstat composition of matter. In the United States, our composition of matter patent coverage extends through 2025. In Europe, our composition of matter patent coverage expires in 2024, and includes patent rights in Germany, France, the United Kingdom, and other member countries of the European Patent Convention. In Japan, our composition of matter patent coverage expires in 2024. Potential five-year patent term extensions may also be available in the United States and Europe, which could extend patent terms in these jurisdictions to 2030 in the United States and 2029 in Europe and Japan, respectively. In some countries, such as the United States, the scope of protection under such patent term extensions, if any, would be defined by the scope of the imetelstat composition of matter as approved. In addition, we have issued patents pertaining to methods of use that extend patent coverage into 2033. The issued U.S. patent covers the treatment of both MF and MDS with imetelstat. The issued European patent covers the treatment of MF with imetelstat. Also, we have received orphan drug designations for both MDS and MF in the United States and for MF in Europe. Orphan drug designation in the United States allows for market exclusivity for up to seven years. Orphan drug designation in Europe allows for market exclusivity for up to ten years.”

Post Reply